HRTX Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Heron Therapeutics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 2.45 USD -3.92%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast HRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HRTX is 7.14 USD with a low forecast of 5.05 USD and a high forecast of 9.45 USD.

HRTX Lowest Forecast

Wall Street Target

HRTX Average Forecast

Wall Street Target

HRTX Highest Forecast

Wall Street Target

106% Upside

191% Upside

286% Upside

The latest public price target was made on Mar 13, 2024 by Serge Belanger from Needham , who expects HRTX stock to rise by 104% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Serge Belanger Needham	5 USD Upside 104%	1 month ago Mar 13, 2024	Heron Therapeutics (HRTX) PT Raised to $5 at Needham to reflect strong sales trends StreetInsider

Price Target	5 USD
Upside/Downside	104%

TMS Co Ltd

216% Upside

Catalyst Pharmaceuticals Inc

83% Upside

Yantai Dongcheng Biochemicals Co Ltd

56% Upside

Hualan Biological Engineering Inc

40% Upside

TMS Co Ltd

216% Upside

Catalyst Pharmaceuticals Inc

83% Upside

Yantai Dongcheng Biochemicals Co Ltd

56% Upside

Hualan Biological Engineering Inc

40% Upside

Design Therapeutics Inc

28% Upside

Chengdu Kanghua Biological Products Co Ltd

38% Upside

Nanjing Vazyme Biotech Co Ltd

65% Upside

Shenzhen Kangtai Biological Products Co Ltd

82% Upside

Revenue
Forecast

The compound annual growth rate of Heron Therapeutics Inc's revenue for the next 3 years is 20%.

N/A

20%

1%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-1%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-44%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for HRTX is 7.14 USD with a low forecast of 5.05 USD and a high forecast of 9.45 USD.

The compound annual growth rate of Heron Therapeutics Inc's revenue for the next 3 years is 20%.

Join more than 132,200+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.